Media Advisory - New Study Aims to Help Youths Better Manage Type 1 Diabetes

OTTAWA, Oct. 27, 2011 /CNW/ - JDRF Canadian Clinical Trial Network (JDRF CCTN) is pleased to announce the launch of the first multi-centre pediatric study in Canada using insulin pump therapy and continuous glucose monitoring (CGM). Based at the Children's Hospital of Eastern Ontario (CHEO) in Ottawa and led by JDRF CCTN researcher, Dr. Margaret Lawson, the study - Timing of Initiation of Continuous Glucose Monitoring in Established Pediatric Diabetes Trial (CGM TIME Trial) - will involve 128 children and teenagers aged five to 18 years old with type 1 diabetes (T1D). The goal of the study is to find better ways for youths to manage the disease, and in particular, determine the best times to introduce CGM usage among this age group.

The Honourable Gary Goodyear, Minister of State for the Federal Economic Development Agency for Southern Ontario (FedDev Ontario) will join JDRF CCTN and Dr. Lawson in this exciting announcement.

Speakers:   Andrew McKee, President and CEO, JDRF Canada
  The Honourable Gary Goodyear, Minister of State (FedDev Ontario)
  Dr. Margaret Lawson, Pediatric Endocrinologist, CHEO
  JDRF Youth Ambassador
   
When:   Thursday, November 3, 2011
  9:00 - 10:00 a.m.
   
Where:   Children's Hospital of Eastern Ontario 401
  Smyth Road, Ottawa
  Room: R154

About JDRF

JDRF is the worldwide leader for research to cure T1D. It sets the global agenda for diabetes research, and is the largest charitable funder and advocate of diabetes science worldwide.

The mission of JDRF is to find a cure for diabetes and its complications through the support of research. T1D is an autoimmune disease that strikes children and adults suddenly, and can be fatal. Until a cure is found, people with T1D have to test their blood sugar and give themselves insulin injections multiple times or use a pump - each day, every day of their lives. And even with that intensive care, insulin is not a cure for diabetes, nor does it prevent its potential complications, which may include kidney failure, blindness, heart disease, stroke, and amputation.

Since its founding in 1970 by parents of children with T1D, JDRF has awarded more than $1.5 billion to diabetes research, including $107 million last year. More than 80 per cent of JDRF's expenditures directly support research and research-related education. For more information, please visit www.jdrf.ca.

About JDRF CCTN

Created in partnership with the Government of Canada, funding for JDRF CCTN came from a commitment of $20 million by the Federal Economic Development Agency for Southern Ontario (FedDev Ontario), with an additional $13.9 million contribution from JDRF. The $33.9 million investment will help accelerate the testing of new technologies and treatments for Canadians and individuals around the world living with T1D and its complications.

JDRF CCTN is a groundbreaking effort to accelerate solutions for the management, care and cure of T1D. JDRF CCTN is currently developing several high-profile clinical trials, in association with leading diabetes researchers at partner universities and medical centers in Southern Ontario. The goal is to position Southern Ontario as an international hub for diabetes translational research, innovation, and commercialization of new therapeutics and enabling technologies. For more information, please visit www.jdrf.ca/cctn.

 

SOURCE Juvenile Diabetes Research Foundation

For further information:

Jennifer McEvoy, JDRF CCTN           Carolyn Carson, Hill & Knowlton
647-789-2024              613-290-0734
jmcevoy@jdrf.ca             carolyn.carson@hillandknowlton.ca

 

Organization Profile

Juvenile Diabetes Research Foundation

More on this organization

JDRF CCTN

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890